NetworkNewsBreaks – Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) Receives Patent for TSC in Five Hypoxia-Related Indications; Shares Rally
Shares of Diffusion Pharmaceuticals (NASDAQ: DFFN) surged as much as 23% this morning after the company announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent for the company’s lead drug candidate, trans sodium crocetinate (TSC). Diffusion’s existing patents currently include the use of TSC in oncology, stroke and neurodegenerative disease indications. The new patent increases coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome. “Receiving the patent from the USPTO validates…







